GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Open-Label Extension Study of the Phase 3 VRX-RET-E22-302 Double-Blind Trial. 115097

Phase 3

Terminated

Conditions: Epilepsy

Interventions: Drug: Retigabine (INN), Ezogabine (USAN)

First Posted Date: 2006-04-03

Last Posted Date: 2018-11-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 376

Registration Number: NCT00310388

Locations: 🇦🇺
Institute of Clniical Neurosciences, Camperdown, New South Wales, Australia
🇦🇺
North Coast Neurology Centre, Maroochydore, Queensland, Australia
🇦🇺
Flinders Medical Centre, Bedford Park, South Australia, Australia

and more 64 locations

Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial

Phase 3

Completed

Conditions: Epilepsy

First Posted Date: 2006-04-03

Last Posted Date: 2020-07-31

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 181

Registration Number: NCT00310375

Locations: 🇲🇽
CIF BIOTEC, Medica Sur, Tlalpan, DF, Mexico
🇲🇽
Antiguo Hospital Civil de Guadalajara, Guadalajara, Jalisco, Mexico
🇺🇸
Neurology Clinic, Northport, Alabama, United States

and more 48 locations

Study to Evaluate the Safety and Immunogenicity of Pandemic Monovalent (H5N1) Influenza Vaccines (Whole Virus Formulation) in Adults 18 and 60 Years of Age

Phase 1

Completed

Conditions: Influenza

Interventions: Biological: Influenza Monovalent Whole virus (H5N1)
Biological: Influenza Monovalent Whole virus (H5N1) adjuvanted vaccine

First Posted Date: 2006-04-03

Last Posted Date: 2017-05-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 400

Registration Number: NCT00309647

Locations: 🇩🇪
GSK Investigational Site, Elmshorn, Schleswig-Holstein, Germany

Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged Between 18 and 60 Years

Phase 1

Completed

Conditions: Influenza

First Posted Date: 2006-04-03

Last Posted Date: 2017-05-10

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 400

Registration Number: NCT00309634

Locations: 🇧🇪
GSK Investigational Site, Gent, Belgium

Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine in Young Males.

Phase 2

Completed

Conditions: Infections, Papillomavirus

Interventions: Biological: Cervarix vaccine
Biological: Engerix-B vaccine

First Posted Date: 2006-03-31

Last Posted Date: 2018-09-17

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 270

Registration Number: NCT00309166

Locations: 🇫🇮
GSK Investigational Site, Tampere, Finland

Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488

Phase 2

Completed

Conditions: Hepatitis B
Tetanus
Haemophilus Influenzae Type b
Diphtheria
Poliomyelitis
Acellular Pertussis

First Posted Date: 2006-03-28

Last Posted Date: 2016-09-23

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 689

Registration Number: NCT00307567

Locations: 🇩🇪
GSK Investigational Site, Berlin, Germany

A Lot-to-lot Consistency (3 Lots of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine) & Non-inferiority Study

Phase 3

Completed

Conditions: Infections, Streptococcal

First Posted Date: 2006-03-28

Last Posted Date: 2016-09-26

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1600

Registration Number: NCT00307554

Locations: 🇵🇱
GSK Investigational Site, Trzebnica, Poland

Safety and Efficacy Study of Investigational Pneumococcal Vaccine in Elderly Population

Phase 2

Completed

Conditions: Prophylaxis Invasive Pneumococcal Diseases and Pneumonia

Interventions: Biological: Pneumococcal vaccine GSK513026
Biological: Pneumovax 23™

First Posted Date: 2006-03-28

Last Posted Date: 2019-10-30

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 146

Registration Number: NCT00307528

Locations: 🇧🇪
GSK Investigational Site, Gent, Belgium

Assess the Immunogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine

Phase 3

Completed

Conditions: Streptococcus Pneumoniae Vaccines
Infections, Streptococcal

First Posted Date: 2006-03-28

Last Posted Date: 2020-01-02

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 120

Registration Number: NCT00307541

Locations: 🇩🇪
GSK Investigational Site, Berlin, Germany

Study to Evaluate the Response Rate to the Licensed Pneumovax 23™ in Elderly Population.

Phase 2

Completed

Conditions: Streptococcus Pneumoniae Vaccines

Interventions: Biological: Pneumovax 23™

First Posted Date: 2006-03-27

Last Posted Date: 2013-04-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1198

Registration Number: NCT00307008

Locations: 🇸🇪
GSK Investigational Site, Västerås, Sweden

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy